Clinical Trial Corner

A phase 1/2a clinical trial examining the effects of a treatment called LAVA-1207 for patients with metastatic prostate cancer has now begun.

A clinical trial to evaluate Descartes-25, a novel allogeneic RNA cell therapy, for multiple myeloma has officially treated its first patient and is now recruiting in certain locations.

A new study to evaluate the accuracy of a blood test for detecting lung cancer in high-risk adults has enrolled its first participant with plans to enroll thousands more.

Enrollment has begun for a trial evaluating a vaccine as first-line maintenance treatment for metastatic, microsatellite-stable colorectal cancer.

A phase 3 trial has begun to examine entospletinib, a selective inhibitor, as a treatment for patients with newly diagnosed NPM1-mutated acute myeloid leukemia.

A phase 2 trial was recently launched to examine the safety and efficacy of oral inhibitor VK-2019 in patients with advanced Epstein-Barr Virus-positive nasopharyngeal carcinoma, a rare type of head and neck cancer, and lymphoma.

The phase 3 COMPOSE trial will look at the efficacy of using 177lu-edotreotide — a novel radiopharmaceutical that is designed to limit radiation exposure to normal tissue — in patients with later stage neuroendocrine tumors.

There are many cancer clinical trials that patients can enroll in across the United States. Here is a snapshot of some of the more recent ones.

City of Hope has opened its first-in-human clinical trial for an investigational therapy in patients with advanced breast cancer.

The first patient was randomized in the phase 2 trial examining Tedopi and Opdivo for non-small cell lung cancer.

Part B of the DIONE-01 study will look at whether IOA-244 increases anti-tumor responses in expansion groups of patients.

A phase 2 trial of aspacytarabine (BST-236) was initiated in patients with AML and MDS.

The TRANSCEND CLL 004 trial is currently enrolling patients to determine the efficacy of a CAR-T cell therapy.

The first patient with bladder cancer was dosed in a phase 1/2 trial examining responses to an investigational immunotherapy.

The first patient has been enrolled in the APOLLO 613 Phase 1/2 clinical trial for CPI-613.

A phase 1 trial of ONO-4685 was initiated for the evaluation of the antibody in patients with relapsed or refractory t-cell lymphoma.

The Food and Drug Administration gave clearance to Bold Therapeutics for a phase 1b/2a trial examining treatments for advanced GI cancers.

The first patients were dosed in a phase 2 trial for a topical gel to treat lesions in patients with colorectal cancer receiving EGFR inhibitor therapy.

Cleveland Clinic’s Lerner Research Institute has initiated a new study to examine a vaccine to prevent triple-negative breast cancer.

A phase 1b trial started to study the effects of fosciclopirox in patients with newly diagnosed and recurrent bladder cancer.

Celsion GmbH has initiated a phase 1 trial to analyze ThermoDox with focused ultrasound for patients with pancreatic cancer.

A company focused on treating underserved patients announced that the first patient with an NTRK fusion was dosed in a phase 2 trial of taletrectinib this summer.

The first patient was enrolled and dosed in InflaRx’s phase 2 trial of vilobelimab for the treatment of cutaneous squamous cell carcinoma.

The PRESERVE 3 trial began this summer to determine efficacy of using Cosela with platinum-based chemotherapy in patients with metastatic bladder cancer.

The first patient was enrolled in a phase 2 clinical trial for the treatment of hormone-sensitive advanced prostate cancer.

Aileron Therapeutics, Inc. announced the initiation of a clinical trial for ALRN-6924, a treatment for patients with non-small cell lung cancer.

A phase 3 clinical trial has begun to evaluate the efficacy and safety of milademetan in patients with de-differentiated liposarcoma.

The first patient was treated in the phase 2b KICKSTART trial testing the safety and efficacy of tomivosertib in combination with Keytruda.